BMO Capital Markets’s $300 target on ABBV

ABBV AbbVie

$248 → $300 (+21%) by Jul 2027

Outperform · raises · said Jul 13, 2026 · 12-month default horizon

Open: judged on the close on Jul 13, 2027

The article this target came from

BMO raises Abbvie stock price target to $300 on Skyrizi strength

Investing.com · Jul 13, 2026

BMO raises Abbvie stock price target to $300 on Skyrizi strength

BMO Capital Markets’s track record → AbbVie →

A fact about what BMO Capital Markets published, as reported by Investing.com, not a recommendation from Dalsna Finance; BMO Capital Markets is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.